Current Knowledge of Heart Failure with Preserved Ejection Fraction

Area of Science:

• Cardiology
• Internal Medicine

Background:

• Heart failure with preserved ejection fraction (HFpEF) is the most prevalent form of heart failure, particularly affecting the elderly.
• Diagnosis relies on clinical data, imaging (left ventricular diastolic dysfunction), and biochemical markers (elevated natriuretic peptide levels with ejection fraction ≥50%).

Discussion:

• Several distinct HFpEF phenotypes have been identified based on etiological and pathophysiological characteristics.
• Understanding these phenotypes enhances knowledge of specific pathogenic mechanisms driving HFpEF.
• Therapeutic strategies, including pharmacological and non-pharmacological agents, are being explored for these phenotypes, but outcomes are currently uncertain.

Key Insights:

• HFpEF diagnosis requires a combination of clinical assessment, echocardiographic findings of diastolic dysfunction, and elevated natriuretic peptides.
• Phenotyping HFpEF is crucial for elucidating underlying disease pathways and guiding targeted treatment development.
• Despite advances in understanding HFpEF subtypes, effective therapeutic interventions remain a significant challenge.

Outlook:

• Further research into HFpEF phenotypes may lead to more personalized and effective treatment approaches.
• Continued investigation into novel pharmacological and non-pharmacological therapies is essential for improving patient outcomes.
• The development of targeted therapies based on specific HFpEF phenotypes holds promise for future clinical practice.